Y-Mabs Therapeutics Profit Margin

Y-Mabs Therapeutics posts a profit margin of -26.03% as of June 2025. That compares with -28.44% in the prior-year period — up 8.5% year over year. That is below the Healthcare sector average of 13.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Y-Mabs Therapeutics's profit margin was -28.44%. The latest reading is -26.03% — a 8.5% year-over-year increase (period ending June 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 13.89% is typical. Y-Mabs Therapeutics's -26.03% is lower that level. That is roughly 287.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Y-Mabs Therapeutics's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -26.03% as of June 2025; use YoY and peer views to separate noise from signal.

Context for YMAB's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.89%), and (3) consistency with growth and profitability. This page covers the first two; Y-Mabs Therapeutics's other metric pages and overview cover the third.